MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
A. Jo Chien(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco), Constantine Godellas(Loyola University Chicago), Rita Nanda(University of Chicago), Angela DeMichele(University of Pennsylvania), Richard B. Schwab(Center for Personalized Cancer Treatment), Henry G. Kaplan(Swedish Medical Center), Andres Forero‐Torres(Kirklin Clinic), Barbara Haley(Shaanxi Research Association for Women and Family), Erin D. Ellis(University of Hawaii Cancer Center), Scott Berry(Queen's University), Amy Wilson(Quantum Leap Healthcare Collaborative), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Teresa Helsten(University of California, San Diego), Ruby Singhrao(University of California, San Francisco), Janice Lu(University of Southern California), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Larissa A. Korde(National Cancer Institute), Nora Jaskowiak(University of Chicago), Katherine Steeg(University of California, San Francisco), Julie E. Lang(University of Southern California), Julia L. Clennell(Berry & Associates (United States)), Erica Stringer-Reasor(University of Alabama at Birmingham), Smita Asare(Quantum Leap Healthcare Collaborative), Kirsten K. Edmiston(Virginia Cancer Institute), Donald W. Northfelt(Mayo Clinic in Arizona), Meredith Buxton(Center for Effective Global Action), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Rebecca K. Viscusi(University of Arizona), Jeffrey B. Matthews(University of California, San Francisco), Kathleen Kemmer(University of Michigan), Garry Peterson(University of California, San Francisco), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Hope S. Rugo(City of Hope), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Melissa Paoloni(National Institutes of Health), Ashish Sanil(Berry & Associates (United States)), Laura J. van’t Veer(University of California, San Francisco), Michelle Melisko(University of California, San Francisco), Debasish Tripathy(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 113
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k